These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37957287)

  • 21. X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation.
    Lee J; Kenward C; Worrall LJ; Vuckovic M; Gentile F; Ton AT; Ng M; Cherkasov A; Strynadka NCJ; Paetzel M
    Nat Commun; 2022 Sep; 13(1):5196. PubMed ID: 36057636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors.
    Kovalevsky A; Aniana A; Coates L; Bonnesen PV; Nashed NT; Louis JM
    J Biol Chem; 2023 Jul; 299(7):104886. PubMed ID: 37271339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
    Dey-Rao R; Smith GR; Timilsina U; Falls Z; Samudrala R; Stavrou S; Melendy T
    Antiviral Res; 2021 Nov; 195():105183. PubMed ID: 34626674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity.
    Stobart CC; Sexton NR; Munjal H; Lu X; Molland KL; Tomar S; Mesecar AD; Denison MR
    J Virol; 2013 Dec; 87(23):12611-8. PubMed ID: 24027335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Identifying SARS-CoV-2 main protease inhibitors by a novel sandwich-like fluorescence polarization screening assay].
    Yan H; Yan G; Qi H; Liu Z; Liu X; Liu X; Li N; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2352-2364. PubMed ID: 35786485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations.
    Parmar M; Thumar R; Patel B; Athar M; Jha PC; Patel D
    Struct Chem; 2022 Nov; ():1-18. PubMed ID: 36467259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
    Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
    Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Discovery of SARS-CoV-2 main protease inhibitors using an optimized FRET-based high-throughput screening assay].
    Yan G; Li D; Qi H; Fu Z; Liu X; Zhang J; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2236-2249. PubMed ID: 35786475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity
    Saramago LC; Santana MV; Gomes BF; Dantas RF; Senger MR; Oliveira Borges PH; Ferreira VNDS; Dos Santos Rosa A; Tucci AR; Dias Miranda M; Lukacik P; Strain-Damerell C; Owen CD; Walsh MA; Ferreira SB; Silva-Junior FP
    J Chem Inf Model; 2023 May; 63(9):2866-2880. PubMed ID: 37058135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sterenin M as a potential inhibitor of SARS-CoV-2 main protease identified from MeFSAT database using molecular docking, molecular dynamics simulation and binding free energy calculation.
    Prajapati J; Patel R; Goswami D; Saraf M; Rawal RM
    Comput Biol Med; 2021 Aug; 135():104568. PubMed ID: 34174757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
    Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
    Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response.
    Liu Y; Qin C; Rao Y; Ngo C; Feng JJ; Zhao J; Zhang S; Wang TY; Carriere J; Savas AC; Zarinfar M; Rice S; Yang H; Yuan W; Camarero JA; Yu J; Chen XS; Zhang C; Feng P
    mBio; 2021 Oct; 12(5):e0233521. PubMed ID: 34544279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biflavonoids from
    Lokhande K; Nawani N; K Venkateswara S; Pawar S
    J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
    Huynh T; Wang H; Luan B
    Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The H163A mutation unravels an oxidized conformation of the SARS-CoV-2 main protease.
    Tran N; Dasari S; Barwell SAE; McLeod MJ; Kalyaanamoorthy S; Holyoak T; Ganesan A
    Nat Commun; 2023 Sep; 14(1):5625. PubMed ID: 37699927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of SARS-CoV-2 M
    Đukić I; Kaličanin N; Sencanski M; Pajovic SB; Milicevic J; Prljic J; Paessler S; Prodanović R; Glisic S
    Front Biosci (Landmark Ed); 2023 Jan; 28(1):8. PubMed ID: 36722278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
    Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 3CL
    Kuo CJ; Liang PH
    FEBS Lett; 2022 May; 596(9):1214-1224. PubMed ID: 35302661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical screening for SARS-CoV-2 main protease inhibitors.
    Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
    PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.